• Voter paralysis

    With so much tilting voters against change, democratic reason is the loser, says Solly Moeng.

  • The power of perseverance

    True grit is a reliable predictor of who will achieve success in life, says Ian Mann.

  • It's the system

    The system sucks and it’s being used far too often as an excuse, says Mandi Smallhorne.

All data is delayed
Loading...
See More

Adcock profits slump on drug loss

Nov 27 2012 08:12
Reuters

(Supplied)

Company Data

ASPEN PHARMACARE HOLDINGS LIMITED [JSE:APN]

Last traded 315
Change 3
% Change 1
Cumulative volume 913482
Market cap 0

Last Updated: 25-05-2016 at 05:00. Prices are delayed by 15 minutes. Source: McGregor BFA

ADCOCK INGRAM HOLDINGS LIMITED [JSE:AIP]

Last traded 42
Change 1
% Change 2
Cumulative volume 29395
Market cap 0

Last Updated: 25-05-2016 at 05:00. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Adcock buys Indian medicine business

Drug firms win R2.5bn tender

Aspen buys GSK Aussie drugs for R2.2bn

Cipla to bid for control of SA affiliate

Cipla mum on why it suspended CEO

Aspen boosts profit, Asian unit robust

 
Johannesburg - South Africa's No 2 drug maker, Adcock Ingram [JSE:AIP], reported a worse-than-expected 9% fall in full-year earnings, hit by the loss of high-margin drugs and unfavourable currency swings.

Adcock said diluted headline earnings per share totalled 422 cents in the year to end-September, from 465c a year earlier.

The results fell short of the 430c forecast by StarMine's SmartEstimate, which gives more weight to forecasts from top rated analysts.

Headline EPS, the main profit gauge in South Africa, excludes certain one-time items.

The company said sales were largely flat at R4.6bn, but it raised its final dividend by 8% to 115c per share.

Adcock has been struggling in recent months after losing three drugs that contributed as much as R200m in sales due to safety reasons while the weaker rand and lower consumer demand added to the headwinds.

Shares in Adcock are down nearly 12% so far this year, far behind its closest rival Aspen Pharmacare [JSE:APN], which has surged more than 60%. 

Follow Fin24 on Twitter, Facebook, Google+ and Pinterest.

adcock ingram  |  earnings reports

NEXT ON FIN24X

 
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
0 comments
Comments have been closed for this article.
 

Company Snapshot

We're talking about:

THE DEBT ISSUE

Debt is one of the biggest financial issues facing South Africans today. Find out how you can avoid and manage your debt with Fin24 and Debt Rescue.
 

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...

Voting Booth

Would you take out a payday loan?

Previous results · Suggest a vote

Loading...